BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Net Debt per Share

The Net Debt per Share of BrightGene Bio-Medical Technology Co (688166.SS) as of Oct 29, 2026 is 3.28 CNY. In the previous year, Net Debt per Share was 3.70 CNY — a change of -11.30% (lower).

Net Debt per Share

3.28CNY

YoY

-11.30%

Last updated:

Net Debt per Share of BrightGene Bio-Medical Technology Co is 2025 3.28 CNY. Net Debt per Share of BrightGene Bio-Medical Technology Co was 2024 3.70 CNY. It decreases by -11.30% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2020
0.18 CNY
Jan 1, 2021
1.46 CNY
Jan 1, 2022
3.73 CNY
Jan 1, 2023
3.82 CNY
Jan 1, 2024
3.70 CNY
Jan 1, 2025
3.28 CNY
The BrightGene Bio-Medical Technology Co Net Debt per Share history
YEARNet Debt per ShareYoY
3.28CNY-11.30%
3.70CNY-3.07%
3.82CNY+2.47%
3.73CNY+154.74%
1.46CNY+698.15%
0.18CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Net Debt per Share of BrightGene Bio-Medical Technology Co is 3.28 CNY in 2025.

Net Debt per Share of BrightGene Bio-Medical Technology Co changed from 3.70 CNY to 3.28 CNY, representing a -11.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Other — BrightGene Bio-Medical Technology Co

Shares OutstandingSupply ChainNet Debt per ShareAssets per Share

All Key Metrics — BrightGene Bio-Medical Technology Co